Results 171 to 180 of about 69,283 (286)

Short-term outcomes of phosphodiesterase type 5 inhibitors for fetal growth restriction: a study protocol for a systematic review with individual participant data meta-analysis, aggregate meta-analysis, and trial sequential analysis. [PDF]

Syst Rev, 2021
Liauw J, Groom K, Ganzevoort W, Gluud C, McKinlay CJD, Sharp A, Mackay L, Kariya C, Lim K, von Dadelszen P, Limpens J, Jakobsen JC, STRIDER Consortium.   +12 more
europepmc   +1 more source

Untargeted Metabolomic and Lipidomic Profiles of Gingival Crevicular Fluid in the Context of Periodontitis

Journal of Clinical Periodontology, EarlyView.
ABSTRACT Aim(s) This cross‐sectional clinical study aimed to explore the untargeted metabolomic and lipidomic profiles in gingival crevicular fluid (GCF) obtained from healthy individuals and patients with periodontitis. Materials and Methods GCF was collected from 17 periodontally healthy and 19 periodontitis patients.
Caroline H. Henderzahs, Chiaki Yamada, Alexandr Morozov, Thelmalane Yalartai, Vanchit John, Hawra AlQallaf, Alexandru Movila   +6 more
wiley   +1 more source

Cost comparison of phosphodiesterase type 5 inhibitors: rural vs urban New York State counties and online pharmacies. [PDF]

Sex Med
Di Scipio SM, Katz A.
europepmc   +1 more source

Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this Phase 3 trial of Japanese patients with moderate to severe PPP (NCT05174065), significantly more patients achieved PPPASI‐50 at Week 16 with apremilast versus placebo. Patient‐reported outcomes, including pruritus and pain/discomfort, also showed significantly greater decreases at Week 16 with apremilast versus placebo.
Tadashi Terui, Yukari Okubo, Satomi Kobayashi, Akimichi Morita, Shinichi Imafuku, Yayoi Tada, Masatoshi Abe, Bruce Strober, Melinda Gooderham, Wendy Zhang, Junichiro Shimauchi, Masafumi Yaguchi, Takeshi Kimura, Ryuichi Ogawa, Hamid Amouzadeh, Masamoto Murakami   +15 more
wiley   +1 more source

Phosphodiesterase type 5 inhibitors combined with traditional Chinese medicine for diabetes mellitus-induced erectile dysfunction: A systematic review and meta-analysis. [PDF]

Medicine (Baltimore)
Xiang L, Liu A, Tang W, Sun B, Yang Y, Li Y, Chen S, Zhao J, Zhang W, Cai X, Tang X.   +10 more
europepmc   +1 more source

Phase 1 study of balinatunfib, an oral inhibitor of TNFR1 signal in mild‐to‐moderate psoriasis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Balinatunfib is the first oral, small molecule selective inhibitor of TNFR1 signaling. The results of this study indicate that balinatunfib treatment was tolerable with no serious or severe adverse events in patients with mild‐to‐moderate psoriasis and showed clinical responses.
Nassr Nassr, Ohn A. Chow, Mai Anh Nguyen, Laurent Perrin, Fabienne Schumacher, Frank‐Dietrich Wagner, Caroline Dreis, Amel Lahmar, Markus Kohlmann, Maria Wiekowski, Tiago R. Matos   +10 more
wiley   +1 more source

French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

Journal of the European Academy of Dermatology and Venereology, EarlyView.
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault, Emilie Brenaut, Marie‐Emeline Marniquet, Carla Berthault, Lea Canoen, Clarisse Marcombes, Audrey Melin, Raphaël Ouakrat, Julie Charles, Stephane Mouret, Olivier Potie, Laetitia Penso, Laura Pina Vegas, Guillaume Larid, Marine Roux, Colombe Bougeard, Sandy Sylvain, Clara Labonne, Tania Randriamiarana, Da Hee Pitaud, Floriane Etheve, Jeremy Gottlieb, Laurie Gouillon, Marine Chastagner, Emilie Sbidian, Hélène Aubert, on behalf of the Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), Hélène Aubert, Marie Masson Regnault, Emilie Brenaut, Emilie Sbidian, Laura Pina Vegas, Laetitia Penso, Jeremy Gottlieb, Marine Roux, Clara Labonne, Tania Randriamiarana, Floriane Etheve, Da Hee Pitaud, Marie‐Emeline Marniquet, Carla Berthault, Clarisse Marcombes, Audrey Melin, Colombe Bougeard, Julie Charles, Olivier Potie, Léa Canoen, Laurie Gouillon, Marine Chastagner, Sandy Sylvain, Guillaume Larid, Raphaël Ouakrat   +51 more
wiley   +1 more source

Utilization Trends of Phosphodiesterase Type-5 Inhibitors for Erectile Dysfunction Between 2019 and 2023 in Tanzania. [PDF]

Cureus
Sangeda RZ, Kadinde AW, Masatu CF, Mwalwisi YH, Yahya-Malima KI, Fimbo AM.   +5 more
europepmc   +1 more source

Engineering the bacterial nutrition strategy to control plant diseases

Journal of Integrative Plant Biology, EarlyView.
This commentary on Wang et al. (2025) and Phan et al. (2025) highlights previously undiscovered Xanthomonas pathways for nutrition acquisition, explains how Xanthomonas bacteria hijack host molecular machinery through their effector proteins, and discusses how these studies can be used to develop new disease resistance mechanisms.
Muhammad Arslan Mahmood, Shahid Mansoor, Muhammad Naveed Aslam   +2 more
wiley   +1 more source

Phosphodiesterase Type 5 Inhibitors in Men With Erectile Dysfunction and the Risk of Alzheimer Disease: A Cohort Study. [PDF]

Neurology
Adesuyan M, Jani YH, Alsugeir D, Howard R, Ju C, Wei L, Brauer R.   +6 more
europepmc   +1 more source